Controlled studies evaluating antiviral therapy plus immunoprophylaxis for protection of perinatal transmission of hepatitis B virus.

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Study | Design | Mothers (T/C) | HBeAg (T/C) | HBV-DNA (copies/ml) | Start time | End time | Vaccine | HBIG | HBsAg at 6-7 mo (NT, nT|NC, nC) | HBsAg at 12 mo (NT, nT|NC, nC) |
| LAM |  |  |  |  |  |  |  |  |  |  |  |
| 26 | Feng, 2007 | NRS | 48/42 | 48/42 | >6 log | 28 w | 4 w after delivery | 10 μg, 0-1-6 | ≥100 IU, 1d | 48, 7|42, 16 | na |
| 27 | Guo, 2008 | RCT | 70/40 | 70/40 | na | 28 w | after delivery | 10 μg, 0-1-6 | 200 IU, 1d, 15d | 70, 3|40, 13 | na |
| 28 | Xu, 2009 | RCT | 61/61 | 61/61 | >9 log | 30-34 w | 4 w after delivery | na, 0-1-6 | 200 IU, 1d | 56, 3|59, 6 | 56, 3|59, 5 |
| 29 | Zhang, 2010 | NRS | 50/50 | 50/50 | >6 log | 28 w | 4 w after delivery | 10 μg, 0-1-6 | 200 IU, 1d, 30d | 50, 3|50, 16 | 50, 1|50, 8 |
| 37 | Wang, 2012# | NRS | 32/27 | 32/27 | >7 log | 28 w | 4 w after delivery | 10 μg, 0-1-6 | 100 IU, 1d, 30d | na | 32, 1|27, 5 |
| 43 | Zeng, 2013 | RCT | 90/30 | 90/30 | >5 log | 28 w | 0, 4, or 6 w after delivery | 10 μg, 0-1-6 | 200 IU, 1d | na | 90, 0|30, 3 |
| 44 | Yu, 2014‡ | NRS | 154/233 | 154/233 | >6 log | 8-32 w | after delivery | 20 μg, 0-1-6 | 200 IU, 1d, 15d | na | 154, 0|233, 0 |
| 45 | Zhang, 2014# | NRS | 55/374 | 55/374 | >6 log | 28-30 w | 4 w after delivery | 10 μg, 0-1-6 | 200 IU, 1d, 15d | na | 52, 0|352, 10 |
| LdT |  |  |  |  |  |  |  |  |  |  |  |
| 30 | Zhao, 2010 | RCT | 30/30 | 30/30 | na | 28 w | after delivery | 10 μg, 0-1-6 | 200 IU, 1d, 30d | na | 30, 1|30, 3 |
| 31 | Guo, 2011 | RCT | 25/25 | 25/25 | >7 log | 28 w | 4 w after delivery | 20 μg, 0-1-6 | 200 IU, 1d, 30d | 28, 6|26, 6 | 28, 4|26, 11 |
| 32 | Han, 2011 | NRS | 135/94 | 135/94 | >7 log | 20-32 w | 4 w after delivery | 20 μg, 0-1-6 | 200 IU, 1d, 15d | 132, 0|88, 7 | na |
| 33 | Yao, 2011 | NRS | 28/30 | na§ | >6 log | 28 w | 4 w after delivery | 10 μg, 0-1-6 | 200 IU, 1d, 30d | 28, 1|30, 5 | 28, 0|30, 4 |
| 34 | Zhou, 2011 | NRS | 36/40 | 34/36 | >7 log | early pregnancy | > 1 year after delivery | 20 μg, 0-1-6 | na | na | 33, 1|34, 6 |
| 35 | Pan, 2012 | NRS | 53/35 | 53/35 | >6 log | 12-30 w | continue | 20 μg, 0-1-6 | 200 IU, 1d, 15d | 52, 0|32, 3 | na |
| 36 | Peng, 2012 | NRS | 40/40 | 40/40 | >6 log | 28 w | after delivery | 10 μg, 0-1-6 | 200 IU, 1d, 30d | 40, 1|40, 10 | 40, 1|40, 10 |
| 37 | Wang, 2012# | NRS | 28/27 | 28/27 | >7 log | 28 w | 4 w after delivery | 10 μg, 0-1-6 | 100 IU, 1d, 30d | na | 28, 0|27, 5 |
| 38 | Wang, 2012 | NRS | 47/198 | 47/198 | >5 log | 12-28 w | after delivery | 10 μg, 0-1-6 | 200 IU, 1d | 47, 0|198, 20 | na |
| 39 | Bai, 2013 | NRS | 30/30 | 30/30 | >7 log | 28-32 w | 4 w after delivery | 10 μg, 0-1-6 | 200 IU, 1d, 30d | 30, 0|30, 4 | na |
| 40 | Jiang, 2013 | NRS | 65/51 | 65/51 | >5 log | 26-30 w | continue | 20 μg, 0-1-6 | 200 IU, na | 65, 1|51, 8 | na |
| 41 | Sun, 2013 | NRS | 38/42 | 38/42 | >7 log | 12 w | 12 w after delivery | 20 μg, 0-1-6 | 200 IU, 1d, 30d | 38, 0|42, 6 | na |
| 42 | Wu, 2013 | NRS | 69/15 | 69/15 | >6 log\* | 24-33 w | na | na, 0-1-6 | na | 70, 0|15, 1 | 70, 0|15, 1 |
| 45 | Zhang, 2014# | NRS | 263/374 | 263/374 | >6 log | 28-30 w | 4 w after delivery | 10 μg, 0-1-6 | 200 IU, 1d, 15d | na | 257, 0|352, 10 |
| TDF |  |  |  |  |  |  |  |  |  |  |  |
| 16 | Celen, 2013 | NRS | 21/24 | 21/24 | >7 log | 18-27 w | 4 w after delivery | 20 μg, 1-2-6 | 200 IU, 1d | 21, 0|23, 2 | na |

T: antiviral treatment; C: control; N: number of infants followed for at least 6 months; n: number of infants positive for HBsAg; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus; HBIG: hepatitis B immunoglobulin; RCT: randomised controlled trial; NRS: non-randomised studies; LAM: lamivudine; LdT: telbivudine; TDF: tenofovir; na: not available.

#Three-armed studies comparing lamivudine, telbivudine, and control.

‡Control group was treated with telbivudine during pregnancy.

§42 positive for HBeAg and 16 negative for HBeAg overall.

\*Presented as IU/ml.